Status:
COMPLETED
DNA-mutation Analysis in Cyst Fluid of Suspected Intraductal Papillary Mucinous Neoplasia of the Pancreas
Lead Sponsor:
Theresienkrankenhaus und St. Hedwig-Klinik GmbH
Collaborating Sponsors:
University Hospital Heidelberg
Conditions:
Pancreas Cyst
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Diagnostic tools are needed to identify mucinous cysts for further evaluation or follow-up respectively to identify cysts with HGD or invasive cancer at an early stage for surgical resection. Molecula...
Detailed Description
Intraductal papillary mucinous neoplasm (IPMN) with low grade dysplasia (LGD) can progress to high grade dysplasia (HGD) or invasive cancer. Main duct IPMN, mixed type IPMN or branch duct IPMN with hi...
Eligibility Criteria
Inclusion
- pancreas cysts with cyst size \> 15mm
- pancreas with main duct dilation \> 5mm
Exclusion
- patients who are not fit for surgery
Key Trial Info
Start Date :
January 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2022
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT03820531
Start Date
January 1 2018
End Date
December 1 2022
Last Update
December 20 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tertiary referral hospital: Theresienkrankenhaus und St. Hedwig Hospital, Academic
Mannheim, Germany, 68165